# Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct04580914` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04580914](<https://clinicaltrials.gov/study/NCT04580914>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04580914

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.

## Technical summary

Registry record NCT04580914. Allocation not applicable; no masking; primary purpose treatment. Start 2021-04-12 (actual); primary completion 2023-06-21 (actual). Results posted on 2025-01-16.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 321 participants (enrolled count; ClinicalTrials.gov record NCT04580914, source copy `cardio:ctgov-nct04580914-2025-01-16`, retrieved 2026-10-26)
- Started: 2021-04-12 (actual) (ClinicalTrials.gov record NCT04580914, source copy `cardio:ctgov-nct04580914-2025-01-16`, retrieved 2026-10-26)
- Primary completion: 2023-06-21 (actual) (ClinicalTrials.gov record NCT04580914, source copy `cardio:ctgov-nct04580914-2025-01-16`, retrieved 2026-10-26)
- Completion: 2023-06-21 (actual) (ClinicalTrials.gov record NCT04580914, source copy `cardio:ctgov-nct04580914-2025-01-16`, retrieved 2026-10-26)
- Results first posted: 2025-01-16 (ClinicalTrials.gov record NCT04580914, source copy `cardio:ctgov-nct04580914-2025-01-16`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Canada; France; Germany; Hong Kong SAR China; Italy; Japan; Monaco; Netherlands; Taiwan; United Kingdom (ClinicalTrials.gov record NCT04580914, source copy `cardio:ctgov-nct04580914-2025-01-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04580914-2025-01-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation
- Acronym: NEwTON AF
- Condition: Paroxysmal Atrial Fibrillation
- Intervention (Device): Treatment with IntellaNav StablePoint Ablation Catheter
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: b304af583484ac8c18428211939c27610cab35257e107b455733377de3fd8615
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
